PCSK9 — Drug Target

All drugs that target PCSK9 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

PCSK9 Inhibitor [EPC] · PCSK9 inhibitor (monoclonal antibody) · PCSK9 inhibitor · PCSK9 inhibitor monoclonal antibody

Marketed (3)

• Repatha · Repatha · PCSK9 Inhibitor [EPC] · Metabolic
  Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL.
• Evolocumab Prefilled Syringe · University of Erlangen-Nürnberg Medical School · PCSK9 inhibitor (monoclonal antibody) · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
• Evolocumab combined with statins · Zibo Central Hospital · PCSK9 inhibitor (monoclonal antibody) · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream, and is combined with statins to achieve greater LDL-lowering efficacy.

Phase 3 pipeline (14)

• VCT220 Tablet · Vincentage Pharma Co., Ltd · PCSK9 inhibitor · Cardiovascular
  VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
• Placebo to Evolocumab · Amgen · PCSK9 inhibitor · Cardiovascular
  Evolocumab works by binding to PCSK9, a protein that regulates cholesterol levels in the blood, thereby increasing the levels of HDL and reducing the levels of LDL.
• SHP615 · Shire · PCSK9 inhibitor · Cardiovascular
  SHP615 is a monoclonal antibody targeting the PCSK9 protein.
• evolocumab and LDL apheresis · Hospital General Universitario Gregorio Marañon · PCSK9 inhibitor · Cardiovascular
  Evolocumab works by binding to PCSK9, a protein that regulates LDL cholesterol levels in the blood, thereby reducing LDL cholesterol production in the liver.
• Evolocumab Pre-filled Syringe · Amgen · PCSK9 inhibitor (monoclonal antibody) · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
• LCS16 · Bayer · PCSK9 inhibitor · Cardiovascular
  LCS16 is a small molecule that inhibits the PCSK9 enzyme.
• cTIV or eTIV_a · Novartis · PCSK9 inhibitor · Cardiovascular
  cTIV is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
• Evolocumab AI/pen · Amgen · PCSK9 inhibitor · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
• Evolocumab AMD · Amgen · PCSK9 inhibitor monoclonal antibody · Cardiovascular
  Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.
• Treatment Prevention for Secondary CV · Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · PCSK9 inhibitor · Cardiovascular
  This drug targets the PCSK9 protein to lower LDL cholesterol levels.
• Treatment with PCSK9 inhibitors · Beijing Anzhen Hospital · PCSK9 inhibitor · Cardiovascular
  PCSK9 inhibitors block the PCSK9 protein, which normally degrades LDL receptors, thereby increasing LDL receptor availability on liver cells to remove more LDL cholesterol from the blood.
• SYH2053/placebo injection · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · PCSK9 inhibitor · Cardiovascular
  SYH2053 is a monoclonal antibody targeting PCSK9.
• RP103 · Amgen · PCSK9 inhibitor · Cardiovascular
  RP103 is a monoclonal antibody targeting PCSK9.
• LCS12 · Bayer · PCSK9 inhibitor · Cardiovascular
  LCS12 is a small molecule that inhibits the PCSK9 enzyme.

Phase 2 pipeline (5)

• Alirocumab Injectable Product · Wolfson Medical Center · PCSK9 inhibitor · Cardiovascular
  Alirocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower low-density lipoprotein cholesterol.
• AGN-210961 Formulation 7 · Allergan · PCSK9 inhibitor · Cardiovascular
  AGN-210961 Formulation 7 is a drug that targets the PCSK9 protein to lower LDL cholesterol.
• AGN-210961 Formulation 5 · Allergan · PCSK9 inhibitor · Cardiovascular
  AGN-210961 Formulation 5 is a medication that targets the PCSK9 protein to lower LDL cholesterol.
• AMG 223 · Amgen Research (Munich) GmbH · PCSK9 inhibitor · Cardiovascular
  AMG 223 is a human monoclonal antibody that targets PCSK9.
• AMG 193 · Amgen · PCSK9 inhibitor · Cardiovascular
  AMG 193 is a monoclonal antibody targeting PCSK9.